Polsky David, Melzer Kate, Hazan Carole, Panageas Katherine S, Busam Klaus, Drobnjak Maria, Kamino Hideko, Spira Joanna G, Kopf Alfred W, Houghton Alan, Cordon-Cardo Carlos, Osman Iman
Department of Dermatology, Medical Center, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA.
J Natl Cancer Inst. 2002 Dec 4;94(23):1803-6. doi: 10.1093/jnci/94.23.1803.
Overexpression of the oncogene HDM2 is observed in a substantial proportion of melanomas, including noninvasive and thin lesions, suggesting that HDM2 overexpression may be an early event in melanocyte transformation. To determine the role of HDM2 in the clinical progression of melanoma, we examined whether its expression was associated with patient survival. From November 1972 through November 1982, 134 patients with melanoma who participated in the New York University Melanoma Cooperative Group were studied, if representative tissues and follow-up were available. HDM2 protein expression was assessed immunohistochemically. Unexpectedly, we observed that HDM2 overexpression was statistically significantly associated with improved disease-free survival (relative risk [RR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.89; two-sided chi(2) P =.021) and overall survival (RR = 0.55, 95% CI = 0.33 to 0.94; two-sided chi(2) P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation.
在相当一部分黑色素瘤中观察到癌基因HDM2的过表达，包括非侵袭性和薄病变，这表明HDM2过表达可能是黑素细胞转化的早期事件。为了确定HDM2在黑色素瘤临床进展中的作用，我们研究了其表达是否与患者生存率相关。从1972年11月到1982年11月，对134名参与纽约大学黑色素瘤合作组的黑色素瘤患者进行了研究，前提是有代表性组织和随访数据。通过免疫组织化学评估HDM2蛋白表达。出乎意料的是，我们观察到在多变量分析中，HDM2过表达与无病生存率提高（相对风险[RR]=0.47，95%置信区间[CI]=0.24至0.89；双侧卡方检验P=0.021）和总生存率提高（RR=0.55，95%CI=0.33至0.94；双侧卡方检验P=0.027）具有统计学显著相关性。HDM2过表达似乎是原发性黑色素瘤患者生存的独立预测因素；然而，需要更大规模的前瞻性研究来验证。
